Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at Cantor Fitzgerald from $15.00 to $25.00. They now have a "neutral" rating on the stock.
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition [Yahoo! Finance]
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at B. Riley from $17.00 to $27.00. They now have a "neutral" rating on the stock.